RE: RNS KEY POINT TO TAKE AWAY11 Aug 2020 11:21
KEY POINTS...
Selective TYK2/JAK1 Inhibitors in Autoimmune Diseases and Cancer
Sareum is continuing to advance its proprietary selective dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as potential once-daily, oral immunotherapy candidates, targeting autoimmune diseases (SDC-1801) and cancers (SDC-1802). Both molecules demonstrate high selectivity for TYK2 and JAK1 kinases, promising early safety data as well as compelling activity in relevant disease models. In addition, both programmes represent unique licensing opportunities for pharmaceutical partners as there are currently no marketed products with the selectivity profile of these molecules.
THIS BIT.....
licensing opportunities for pharmaceutical partners as there are currently no marketed products with the selectivity profile of these molecules.?????????? that's a big statement that we are wort a lot more...…
perhaps we will hear a lot more from the presentation on Friday 14th AUG 10AM
looking forward to that..
308